Astrazeneca

FromAstraZeneca ([email protected])
Subject (150)imfinzi-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-tria
Preheader (150)Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III t
Typography
Arial
Colors
Text Analysis
Body Words146
Subject Words1
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px770 px
X-Spam Score-0.2
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

imfinzi-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-tria

Imfinzi regimen reduced risk of progression, recurrence or death by 29% in early-stage gastric cancer vs. chemotherapy alone in MATTERHORN Phase III t
imfinzi-regimen-reduced-risk-of-progression-recurrence-or-death-by-29-in-early-stage-gastric-cancer-vs-chemotherapy-alone-in-matterhorn-phase-iii-tria